File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Pretreatment gamma‐glutamyl transferase predicts mortality in patients with chronic hepatitis B treated with nucleotide/nucleoside analogs

TitlePretreatment gamma‐glutamyl transferase predicts mortality in patients with chronic hepatitis B treated with nucleotide/nucleoside analogs
Authors
KeywordsGGT
HBV
mortality
NA
treatment
Issue Date27-Oct-2023
PublisherWiley Open Access
Citation
Kaohsiung Journal of Medical Sciences, 2023, p. n/a-n/a How to Cite?
Abstract

Elevated serum gamma-glutamyl transferase (GGT) levels are associated with chronic hepatitis B (CHB)-related hepatocellular carcinoma. However, their role in predictingmortality in patients with CHB treated with nucleotide/nucleoside analogs (NAs) remains elusive. Altogether, 2843 patients with CHB treated with NAs were recruited from a multinational cohort. Serum GGT levels before and 6 months (Month-6) after initiating NAs were measured to explore their association with all-cause, liver-related, and non-liver-related mortality. The annual incidence of all-cause mortality was 0.9/100 person-years over a follow-up period of 17,436.3 person-years. Compared with patients who survived, those who died had a significantly higher pretreatment (89.3 vs. 67.4 U/L,p=0.002) and Month-6-GGT levels (62.1vs. 38.4 U/L, p< 0.001). The factors associated with all-cause mortality included cir-rhosis (hazard ratio [HR]/95% confidence interval [CI]: 2.66/1.92–3.70,p< 0.001), pretreatment GGT levels (HR/CI: 1.004/1.003–1.006, p< 0.001), alanine aminotrans-ferase level (HR/CI: 0.996/0.994–0.998, p=0.001), and age (HR/CI: 1.06/1.04–1.07, p< 0.001). Regarding liver-related mortality, the independent factors includedcirrhosis (HR/CI: 4.36/2.79–6.89,p< 0.001), pretreatment GGT levels (HR/CI:1.006/1.004–1.008, p< 0.001), alanine aminotransferase level (HR/CI: 0.993/0.990–0.997, p=0.001), age (HR/CI: 1.03/1.01–1.05,p< 0.001), and fatty liver disease(HR/CI: 0.30/0.15–0.59,p=0.001). Pretreatment GGT levels were also indepen-dently  predictive  of  non-liver-related  mortality  (HR/CI:  1.003/1.000–1.005, p=0.03). The results remained consistent after excluding the patients with a history of alcohol use. A dose-dependent manner of <25, 25–75, and >75 percentile of pre-treatment GGT levels was observed with respect to the all-cause mortality (trendp< 0.001). Pretreatment serum GGT levels predicted all-cause, liver-related, andnon-liver-related mortality in patients with CHB treated with NAs.


Persistent Identifierhttp://hdl.handle.net/10722/339004
ISSN
2023 Impact Factor: 2.7
2023 SCImago Journal Rankings: 0.623
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorJang, TY-
dc.contributor.authorLiang, PC-
dc.contributor.authorJun, DW-
dc.contributor.authorJung, JH-
dc.contributor.authorToyoda, H-
dc.contributor.authorWang, CW-
dc.contributor.authorYuen, MF-
dc.contributor.authorCheung, KS-
dc.contributor.authorYasuda, S-
dc.contributor.authorKim, SE-
dc.contributor.authorYoon, EL-
dc.contributor.authorAn, J-
dc.contributor.authorEnomoto, M-
dc.contributor.authorKozuka, R-
dc.contributor.authorChuma, M-
dc.contributor.authorNozaki, A-
dc.contributor.authorIshikawa, T-
dc.contributor.authorWatanabe, T-
dc.contributor.authorAtsukawa, M-
dc.contributor.authorArai, T-
dc.contributor.authorHayama, K-
dc.contributor.authorIshigami, M-
dc.contributor.authorCho, YK-
dc.contributor.authorOgawa, E-
dc.contributor.authorKim, HS-
dc.contributor.authorShim, JJ-
dc.contributor.authorUojima, H-
dc.contributor.authorJeong, SW-
dc.contributor.authorAhn, SB-
dc.contributor.authorTakaguchi, K-
dc.contributor.authorSenoh, T-
dc.contributor.authorButi, M-
dc.contributor.authorVargas-Accarino, E-
dc.contributor.authorAbe, H-
dc.contributor.authorTakahashi, H-
dc.contributor.authorInoue, K-
dc.contributor.authorHuang, JF-
dc.contributor.authorChuang, WL-
dc.contributor.authorYeh, ML-
dc.contributor.authorDai, CY-
dc.contributor.authorHuang, CF-
dc.contributor.authorNguyen, MH-
dc.contributor.authorYu, ML-
dc.date.accessioned2024-03-11T10:33:07Z-
dc.date.available2024-03-11T10:33:07Z-
dc.date.issued2023-10-27-
dc.identifier.citationKaohsiung Journal of Medical Sciences, 2023, p. n/a-n/a-
dc.identifier.issn1607-551X-
dc.identifier.urihttp://hdl.handle.net/10722/339004-
dc.description.abstract<p>Elevated serum gamma-glutamyl transferase (GGT) levels are associated with chronic hepatitis B (CHB)-related hepatocellular carcinoma. However, their role in predictingmortality in patients with CHB treated with nucleotide/nucleoside analogs (NAs) remains elusive. Altogether, 2843 patients with CHB treated with NAs were recruited from a multinational cohort. Serum GGT levels before and 6 months (Month-6) after initiating NAs were measured to explore their association with all-cause, liver-related, and non-liver-related mortality. The annual incidence of all-cause mortality was 0.9/100 person-years over a follow-up period of 17,436.3 person-years. Compared with patients who survived, those who died had a significantly higher pretreatment (89.3 vs. 67.4 U/L,p=0.002) and Month-6-GGT levels (62.1vs. 38.4 U/L, p< 0.001). The factors associated with all-cause mortality included cir-rhosis (hazard ratio [HR]/95% confidence interval [CI]: 2.66/1.92–3.70,p< 0.001), pretreatment GGT levels (HR/CI: 1.004/1.003–1.006, p< 0.001), alanine aminotrans-ferase level (HR/CI: 0.996/0.994–0.998, p=0.001), and age (HR/CI: 1.06/1.04–1.07, p< 0.001). Regarding liver-related mortality, the independent factors includedcirrhosis (HR/CI: 4.36/2.79–6.89,p< 0.001), pretreatment GGT levels (HR/CI:1.006/1.004–1.008, p< 0.001), alanine aminotransferase level (HR/CI: 0.993/0.990–0.997, p=0.001), age (HR/CI: 1.03/1.01–1.05,p< 0.001), and fatty liver disease(HR/CI: 0.30/0.15–0.59,p=0.001). Pretreatment GGT levels were also indepen-dently  predictive  of  non-liver-related  mortality  (HR/CI:  1.003/1.000–1.005, p=0.03). The results remained consistent after excluding the patients with a history of alcohol use. A dose-dependent manner of <25, 25–75, and >75 percentile of pre-treatment GGT levels was observed with respect to the all-cause mortality (trendp< 0.001). Pretreatment serum GGT levels predicted all-cause, liver-related, andnon-liver-related mortality in patients with CHB treated with NAs.<br></p>-
dc.languageeng-
dc.publisherWiley Open Access-
dc.relation.ispartofKaohsiung Journal of Medical Sciences-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectGGT-
dc.subjectHBV-
dc.subjectmortality-
dc.subjectNA-
dc.subjecttreatment-
dc.titlePretreatment gamma‐glutamyl transferase predicts mortality in patients with chronic hepatitis B treated with nucleotide/nucleoside analogs-
dc.typeArticle-
dc.identifier.doi10.1002/kjm2.12771-
dc.identifier.scopuseid_2-s2.0-85175006795-
dc.identifier.spagen/a-
dc.identifier.epagen/a-
dc.identifier.isiWOS:001096107200001-
dc.identifier.issnl1607-551X-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats